Anti‐sulfatide IgM antibodies in peripheral neuropathy: to test or not to test?

Giannotta, Claudia; Pietro, Davide Antonio Di; Gallia, Francesca; Nobile‐Orazio, Eduardo

doi:10.1111/ene.12658

Cited by 19 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extension of antibody reactivity to various HNK-1 bearing proteins other than MAG, might be associated with treatment resistance [ 40 ]. Some ‘anti-MAG’ antibodies also react with sulfatides (3-sulphated galactocerebroside) [ 46 ]. It is also noteworthy that some cases of CIDP may harbour anti-SGPGantibodies [ 47 ].…”

Section: Anti-myelin Associated Glycoprotein (Mag) Antibodiesmentioning

confidence: 99%

Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders

Delmont

Willison

2015

JND

View full text Add to dashboard Cite

A wide range of autoantibodies have been described in immune-mediated nerve disorders that target glycans borne by glycolipids and glycoproteins enriched in the peripheral nerves. Their use as diagnostic biomarkers is very widespread, despite some limitations on sensitivity and specificity, and the lack of standardized assays and access to quality assurance schemes. Although many methods have been applied to measurement, ELISA, in the form of commercial kits or in-house assays, still remains the most widely available and convenient assay methodology.Some antibodies have a particularly robust and widely appreciated clinical significance. Thus, the anti-MAG IgM antibodies that are found in IgM paraprotein related neuropathies define a relatively uniform clinical and prognostic phenotype. IgG antibodies against gangliosides GM1 and GD1a are strongly associated with motor axonal variants of Guillain-Barré syndrome, and anti-GQ1b with Miller Fisher syndrome. In other chronic neuropathies, antibodies against disialylated gangliosides including GD1b and GD3 are detected in ataxic neuropathies, usually associated with an IgM paraprotein, and antibodies against GM1 and the complex GM1:GalC are frequently found in multifocal motor neuropathy. Unfortunately, autoantibodies strongly associated with the diagnosis of chronic inflammatory demyelinating polyneuropathies and with demyelinating forms of GBS are still lacking.Identification of autoantibodies that map onto a specific clinical phenotype not only allows for improved classification, but also provides better understanding of the pathophysiology of inflammatory neuropathies and the potential for therapeutic interventions.

show abstract

Section: Anti-myelin Associated Glycoprotein (Mag) Antibodiesmentioning

confidence: 99%

Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders

Delmont

Willison

2015

JND

View full text Add to dashboard Cite

show abstract

“…Antibodies binding to sulfatide have been predominantly linked with demyelinating neuropathies, consistent with the abundance of the glycolipid in myelin, but have also been associated with neuropathies characterised by prominent axonal loss ( Carpo et al, 2000 ). Overall, evidence indirectly indicates that anti-sulfatide antibodies are associated with a proportion of autoimmune neuropathy cases and may play a role in pathogenesis; however experimental evidence on causality is lacking and their use as a diagnostic or prognostic factor is still uncertain ( Giannotta et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Differential binding patterns of anti-sulfatide antibodies to glial membranes

Meehan

McGonigal

Cunningham

et al. 2018

Journal of Neuroimmunology

View full text Add to dashboard Cite

Sulfatide is a major glycosphingolipid in myelin and a target for autoantibodies in autoimmune neuropathies. However neuropathy disease models have not been widely established, in part because currently available monoclonal antibodies to sulfatide may not represent the diversity of anti-sulfatide antibody binding patterns found in neuropathy patients. We sought to address this issue by generating and characterising a panel of new anti-sulfatide monoclonal antibodies. These antibodies have sulfatide reactivity distinct from existing antibodies in assays and in binding to peripheral nerve tissues and can be used to provide insights into the pathophysiological roles of anti-sulfatide antibodies in demyelinating neuropathies.

show abstract

“…Whilst neuropathy with anti‐MAG antibodies presents with homogeneous clinical, neurophysiological and pathological features, anti‐sulfatide antibodies are associated with heterogeneous clinical pictures and their pathogenic role is still controversial. Their diagnostic relevance is actually limited by modest sensitivity and specificity that can only attest feeble clinical‐serological correlations, which are further complicated by a frequent concomitant reactivity with MAG and a possible cross‐reactivity due to common sulfated epitopes .…”

Section: Introductionmentioning

confidence: 99%